Hikma Delivers Robust First Half Results and Reinforces Growth Expectations for Second Half
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, has reported its Interim Results for the six months ended 30 June 2025. Riad Mishlawi, Chief Executive Officer of Hikma, said: “In the first half of 2025, the strategic changes and renewed focus we put in place
